探討SPZ 1 在慢性骨髓性白血病中癌幹細胞特性之研究

To explore the potential regulatory effect of SPZ 1 on the cancer stem cells’ properties in chronic myeloid leukemia

賴健瑜(Kean-Yee, Lai)

指導教授 ： 許世賢

共同指導教授 ： 邱世欣(Shyh-Shin Chiou)

高雄醫學大學/醫學院/醫學研究所碩士班/碩士(2016年)

摘要

none

關鍵字

SPZ 1 ； 慢性骨髓性白血病 ； 癌幹細胞

並列摘要

Chronic myeloid leukemia (CML) is a disease of hematopoietic stem cells arising from spontaneous chromosomal translocation. Epidemiology studies showed a slight male preponderance and women has a survival advantage over men. The mechanism of spontaneous chromosomal translocation is still unknown.
Basic helix-loop helix transcription factor (bHLH) has a key role during embryogenesis, regardless cell proliferation, cell growth and differentiation. Spermatogenesis specific leucine zipper 1 (SPZ 1) is one of the bHLH family members. It’s also known as proto-oncogene. The objective of the present thesis was to explore the potential regulatory effect of SPZ 1 on the cancer stem cells’ properties in CML. K562 is a CML cell line. By conducting lentivirus vector transduction method, SPZ 1 cDNA was overexpressed in K562 cell line. An increased of cell growth was observed. However, when knocked down SPZ 1 gene (SPZ 1 sh-RNAi) was transfected into K562, cell growth was restricted. Thus, in this study, the cancer stem cells’ properties were observed by comparing K562 empty vector cells, K562-Spz1 overexpressed cells, and K562-shSPZ1 cells. Western blot analysis, real-time-PCR, Fluorescence-activated cell sorting (FACS) were done. Results showed that enhanced Spz1 expression leads to cell growth acceleration whereas knocked down of Spz1 inhibited cell growth. Furthermore, enhanced Spz1 also increased factors associated with stem cell properties. Thus, these results concluded that Spz1 acted as modulator of cancer stem cells properties in CML.

並列關鍵字

SPZ 1 ； Cancer stem cell ； Chronic myelois leukemia

參考文獻

1. Fialkow P. J., Jacobson R. J., and Papayannopoulou T., Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med, 1977. 63(1): p. 125-30.

2. Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., and Kantarjian H. M., The biology of chronic myeloid leukemia. N Engl J Med, 1999. 341(3): p. 164-72.

3. Sawyers C. L., Chronic myeloid leukemia. N Engl J Med, 1999. 340(17): p. 1330-40.

4. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for the survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 1998; 90: 850–58.

5. Berger U, Maywald O, Pfirrman M, et al. Gender aspects in chronic myeloid leukemia: long term results from randomized studies. Leukemia 2005; 19: 984–89.